Access to innovation through the national early access program and clinical trials for patients with malignant melanoma

BACKGROUND: The arrival of immunotherapies and targeted therapies challenged the authorities to make them available as soon as possible. France has effective tools, such as clinical trials (CTs) and a national early access program (temporary authorizations for use [ATUs] and temporary recommendation...

Descripción completa

Detalles Bibliográficos
Autores principales: Christen, Claire, Belgodère, Laetitia, Guillot, Bernard, Jumeau, Céline, Lorence, Annie, Kerouani‐Lafaye, Ghania, Brunel, Liora, Turcry, Florence, Monard, Adrien, Grudé, Francoise, Guyader, Gaëlle, Boudali, Lotfi, Albin, Nicolas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8252498/
https://www.ncbi.nlm.nih.gov/pubmed/33764524
http://dx.doi.org/10.1002/cncr.33492

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8252498/
https://www.ncbi.nlm.nih.gov/pubmed/33764524
http://dx.doi.org/10.1002/cncr.33492

Ejemplares similares